Krystal Biotech, Inc. KRYS Japan — Product revenue, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s japan — product revenue, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s japan — product revenue, net?
- Krystal Biotech, Inc. (KRYS) reported japan — product revenue, net of $8.19M in Q1 2026.
- What does japan — product revenue, net mean?
- The total net sales of products sold by the company within Japan.
- How do you interpret japan — product revenue, net?
- An increase indicates successful commercial adoption and effective distribution of the company's therapies in Japan, while a decrease may signal competitive pressure, regulatory hurdles, or market saturation.
- How does japan — product revenue, net compare across companies?
- Comparable to regional revenue disclosures for other biopharmaceutical companies, often benchmarked against total international revenue or specific major market performance metrics.